{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:59:50Z","timestamp":1793408390542,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UG3AI150550"],"award-info":[{"award-number":["UG3AI150550"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL125016"],"award-info":[{"award-number":["R01HL125016"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The continuing emergence of new strains of antibiotic-resistant bacteria has renewed interest in phage therapy; however, there has been limited progress in applying phage therapy to multi-drug resistant\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    (\n                    <jats:italic>Mtb<\/jats:italic>\n                    ) infections. In this study, we show that bacteriophage strains D29 and DS6A can efficiently lyse\n                    <jats:italic>Mtb<\/jats:italic>\n                    H37Rv in 7H10 agar plates. However, only phage DS6A efficiently kills H37Rv in liquid culture and in\n                    <jats:italic>Mtb<\/jats:italic>\n                    -infected human primary macrophages. We further show in subsequent experiments that, after the humanized mice were infected with aerosolized H37Rv, then treated with DS6A intravenously, the DS6A treated mice showed increased body weight and improved pulmonary function relative to control mice. Furthermore, DS6A reduces\n                    <jats:italic>Mtb<\/jats:italic>\n                    load in mouse organs with greater efficacy in the spleen. These results demonstrate the feasibility of developing phage therapy as an effective therapeutic against\n                    <jats:italic>Mtb<\/jats:italic>\n                    infection.\n                  <\/jats:p>","DOI":"10.1038\/s42003-024-06006-x","type":"journal-article","created":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T02:01:36Z","timestamp":1709949696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Bacteriophage therapy for the treatment of Mycobacterium tuberculosis infections in humanized mice"],"prefix":"10.1038","volume":"7","author":[{"given":"Fan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Labani-Motlagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6715-1757","authenticated-orcid":false,"given":"Jose Alejandro","family":"Bohorquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josimar Dornelas","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danish","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Florence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Vankayalapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Ikebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramakrishna","family":"Vankayalapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9678-4529","authenticated-orcid":false,"given":"John J.","family":"Dennehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3608-4790","authenticated-orcid":false,"given":"Buka","family":"Samten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8075-5478","authenticated-orcid":false,"given":"Guohua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,9]]},"reference":[{"key":"6006_CR1","doi-asserted-by":"publisher","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","volume":"13","author":"RM Houben","year":"2016","unstructured":"Houben, R. M. & Dodd, P. J. The Global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 13, e1002152 (2016).","journal-title":"PLoS Med."},{"key":"6006_CR2","doi-asserted-by":"publisher","unstructured":"Bates, M., Marais, B. J. & Zumla, A. Tuberculosis comorbidity with communicable and noncommunicable diseases. Cold Spring Harb Perspect. Med. 5, https:\/\/doi.org\/10.1101\/cshperspect.a017889 (2015).","DOI":"10.1101\/cshperspect.a017889"},{"key":"6006_CR3","doi-asserted-by":"publisher","first-page":"612675","DOI":"10.3389\/fmicb.2021.612675","volume":"12","author":"A Allue-Guardia","year":"2021","unstructured":"Allue-Guardia, A., Garcia, J. I. & Torrelles, J. B. Evolution of drug-resistant mycobacterium tuberculosis strains and their adaptation to the human lung environment. Front. Microbiol. 12, 612675 (2021).","journal-title":"Front. Microbiol."},{"key":"6006_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10975-7","volume":"10","author":"JJ Lee","year":"2019","unstructured":"Lee, J. J. et al. Transient drug-tolerance and permanent drug-resistance rely on the trehalose-catalytic shift in Mycobacterium tuberculosis. Nat. Commun. 10, 2928 (2019).","journal-title":"Nat. Commun."},{"key":"6006_CR5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.tim.2022.02.005","volume":"30","author":"B Trubenova","year":"2022","unstructured":"Trubenova, B., Roizman, D., Moter, A., Rolff, J. & Regoes, R. R. Population genetics, biofilm recalcitrance, and antibiotic resistance evolution. Trends Microbiol 30, 841\u2013852 (2022).","journal-title":"Trends Microbiol"},{"key":"6006_CR6","unstructured":"World Health Organization, Global Tuberculosis Report 2021. (2021)."},{"key":"6006_CR7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/14787210.2019.1689818","volume":"17","author":"MH Ali","year":"2019","unstructured":"Ali, M. H. et al. Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications. Expert Rev. Anti Infect. Ther. 17, 927\u2013937 (2019).","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"6006_CR8","doi-asserted-by":"publisher","unstructured":"Liu, C., Hong, Q., Chang, R. Y. K., Kwok, P. C. L. & Chan, H. K. Phage-antibiotic therapy as a promising strategy to combat multidrug-resistant infections and to enhance antimicrobial efficiency. Antibiotics 11, https:\/\/doi.org\/10.3390\/antibiotics11050570 (2022).","DOI":"10.3390\/antibiotics11050570"},{"key":"6006_CR9","doi-asserted-by":"publisher","unstructured":"Allue-Guardia, A., Saranathan, R., Chan, J. & Torrelles, J. B. Mycobacteriophages as potential therapeutic agents against drug-resistant tuberculosis. Int. J. Mol. Sci. 22, https:\/\/doi.org\/10.3390\/ijms22020735 (2021).","DOI":"10.3390\/ijms22020735"},{"key":"6006_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4292\/wjgpt.v8.i3.162","volume":"8","author":"DM Lin","year":"2017","unstructured":"Lin, D. M., Koskella, B. & Lin, H. C. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J. Gastrointest. Pharm. Ther. 8, 162\u2013173, (2017).","journal-title":"World J. Gastrointest. Pharm. Ther."},{"key":"6006_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/jpids\/pix056","volume":"7","author":"C Duplessis","year":"2018","unstructured":"Duplessis, C. et al. Refractory Pseudomonas Bacteremia in a 2-Year-Old sterilized by bacteriophage therapy. J. Pediatr. Infect. Dis. Soc. 7, 253\u2013256 (2018).","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"6006_CR12","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1099\/jmm.0.029744-0","volume":"60","author":"A Khawaldeh","year":"2011","unstructured":"Khawaldeh, A. et al. Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. J. Med. Microbiol. 60, 1697\u20131700 (2011).","journal-title":"J. Med. Microbiol."},{"key":"6006_CR13","doi-asserted-by":"publisher","first-page":"ofy064","DOI":"10.1093\/ofid\/ofy064","volume":"5","author":"S LaVergne","year":"2018","unstructured":"LaVergne, S. et al. Phage therapy for a multidrug-resistant acinetobacter baumannii craniectomy site infection. Open Forum Infect. Dis. 5, ofy064 (2018).","journal-title":"Open Forum Infect. Dis."},{"key":"6006_CR14","doi-asserted-by":"publisher","unstructured":"Schooley, R. T. et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant acinetobacter baumannii infection. Antimicrob. Agents Chemother. 61, https:\/\/doi.org\/10.1128\/AAC.00954-17 (2017).","DOI":"10.1128\/AAC.00954-17"},{"key":"6006_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1749-4486.2009.01973.x","volume":"34","author":"A Wright","year":"2009","unstructured":"Wright, A., Hawkins, C. H., Anggard, E. E. & Harper, D. R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34, 349\u2013357 (2009).","journal-title":"Clin. Otolaryngol."},{"key":"6006_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/emph\/eoy005","volume":"2018","author":"BK Chan","year":"2018","unstructured":"Chan, B. K. et al. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol. Med. Public Health 2018, 60\u201366 (2018).","journal-title":"Evol. Med. Public Health"},{"key":"6006_CR17","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","volume":"25","author":"RM Dedrick","year":"2019","unstructured":"Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730\u2013733 (2019).","journal-title":"Nat. Med."},{"key":"6006_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29689-4","volume":"13","author":"JS Little","year":"2022","unstructured":"Little, J. S. et al. Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection. Nat. Commun. 13, 2313 (2022).","journal-title":"Nat. Commun."},{"key":"6006_CR19","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.cell.2022.04.024","volume":"185","author":"JA Nick","year":"2022","unstructured":"Nick, J. A. et al. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell 185, 1860\u20131874.e1812 (2022).","journal-title":"Cell"},{"key":"6006_CR20","doi-asserted-by":"publisher","unstructured":"Guerrero-Bustamante, C. A., Dedrick, R. M., Garlena, R. A., Russell, D. A. & Hatfull, G. F. Toward a phage cocktail for tuberculosis: susceptibility and tuberculocidal action of mycobacteriophages against diverse mycobacterium tuberculosis strains. mBio 12, https:\/\/doi.org\/10.1128\/mBio.00973-21 (2021).","DOI":"10.1128\/mBio.00973-21"},{"key":"6006_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00203-014-0954-6","volume":"196","author":"Y Gan","year":"2014","unstructured":"Gan, Y., Wu, T., Liu, P. & Guo, S. Characterization and classification of Bo4 as a cluster G mycobacteriophage that can infect and lyse M. tuberculosis. Arch. Microbiol. 196, 209\u2013218 (2014).","journal-title":"Arch. Microbiol."},{"key":"6006_CR22","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.2147\/IDR.S218638","volume":"12","author":"T Azimi","year":"2019","unstructured":"Azimi, T. et al. Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review. Infect. Drug Resist. 12, 2943\u20132959 (2019).","journal-title":"Infect. Drug Resist."},{"key":"6006_CR23","doi-asserted-by":"publisher","first-page":"16076","DOI":"10.1038\/nrdp.2016.76","volume":"2","author":"M Pai","year":"2016","unstructured":"Pai, M. et al. Tuberculosis. Nat. Rev. Dis. Prim. 2, 16076 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"6006_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fimmu.2019.00089","volume":"10","author":"F Arrey","year":"2019","unstructured":"Arrey, F. et al. Humanized mouse model mimicking pathology of human tuberculosis for in vivo evaluation of drug regimens. Front. Immunol. 10, 89 (2019).","journal-title":"Front. Immunol."},{"key":"6006_CR25","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1128\/AAC.00217-12","volume":"56","author":"ER Driver","year":"2012","unstructured":"Driver, E. R. et al. Evaluation of a mouse model of necrotic granuloma formation using C3HeB\/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56, 3181\u20133195 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"6006_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13567-017-0477-7","volume":"48","author":"M Boute","year":"2017","unstructured":"Boute, M. et al. The C3HeB\/FeJ mouse model recapitulates the hallmark of bovine tuberculosis lung lesions following Mycobacterium bovis aerogenous infection. Vet. Res. 48, 73 (2017).","journal-title":"Vet. Res."},{"key":"6006_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/iid3.124","volume":"4","author":"S Jangalwe","year":"2016","unstructured":"Jangalwe, S., Shultz, L. D., Mathew, A. & Brehm, M. A. Improved B cell development in humanized NOD-scid IL2Rgamma(null) mice transgenically expressing human stem cell factor, granulocyte-macrophage colony-stimulating factor and interleukin-3. Immun. Inflamm. Dis. 4, 427\u2013440 (2016).","journal-title":"Immun. Inflamm. Dis."},{"key":"6006_CR28","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1089\/scd.2015.0289","volume":"25","author":"AM Coughlan","year":"2016","unstructured":"Coughlan, A. M. et al. Myeloid engraftment in humanized mice: impact of granulocyte-colony stimulating factor treatment and transgenic mouse strain. Stem Cells Dev. 25, 530\u2013541 (2016).","journal-title":"Stem Cells Dev."},{"key":"6006_CR29","doi-asserted-by":"publisher","first-page":"e63331","DOI":"10.1371\/journal.pone.0063331","volume":"8","author":"VE Calderon","year":"2013","unstructured":"Calderon, V. E. et al. A humanized mouse model of tuberculosis. PLoS One 8, e63331 (2013).","journal-title":"PLoS One"},{"key":"6006_CR30","doi-asserted-by":"publisher","unstructured":"Yu, C. I. et al. Human KIT+ myeloid cells facilitate visceral metastasis by melanoma. J. Exp. Med. 218, https:\/\/doi.org\/10.1084\/jem.20182163 (2021).","DOI":"10.1084\/jem.20182163"},{"key":"6006_CR31","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1182\/blood-2010-08-301507","volume":"117","author":"E Billerbeck","year":"2011","unstructured":"Billerbeck, E. et al. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rgamma(null) humanized mice. Blood 117, 3076\u20133086 (2011).","journal-title":"Blood"},{"key":"6006_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/0300985820970144","volume":"58","author":"LJ Janke","year":"2021","unstructured":"Janke, L. J. et al. Development of Mast Cell and Eosinophil Hyperplasia and HLH\/MAS-Like Disease in NSG-SGM3 Mice Receiving Human CD34+ Hematopoietic Stem Cells or Patient-Derived Leukemia Xenografts. Vet. Pathol. 58, 181\u2013204 (2021).","journal-title":"Vet. Pathol."},{"key":"6006_CR33","doi-asserted-by":"publisher","unstructured":"Terahara, K., Iwabuchi, R. & Tsunetsugu-Yokota, Y. Perspectives on Non-BLT humanized mouse models for studying HIV pathogenesis and therapy. Viruses 13, https:\/\/doi.org\/10.3390\/v13050776 (2021).","DOI":"10.3390\/v13050776"},{"key":"6006_CR34","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1073\/pnas.1019682108","volume":"108","author":"T Willinger","year":"2011","unstructured":"Willinger, T. et al. Human IL-3\/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. Proc. Natl. Acad. Sci. USA 108, 2390\u20132395 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"6006_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.virol.2012.09.026","volume":"434","author":"D Jacobs-Sera","year":"2012","unstructured":"Jacobs-Sera, D. et al. On the nature of mycobacteriophage diversity and host preference. Virology 434, 187\u2013201 (2012).","journal-title":"Virology"},{"key":"6006_CR36","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.3389\/fimmu.2019.02139","volume":"10","author":"P Cardona","year":"2019","unstructured":"Cardona, P. & Cardona, P. J. Regulatory T Cells in Mycobacterium tuberculosis Infection. Front. Immunol. 10, 2139 (2019).","journal-title":"Front. Immunol."},{"key":"6006_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-1-4614-6111-1_9","volume":"783","author":"RP Larson","year":"2013","unstructured":"Larson, R. P., Shafiani, S. & Urdahl, K. B. Foxp3(+) regulatory T cells in tuberculosis. Adv. Exp. Med. Biol. 783, 165\u2013180 (2013).","journal-title":"Adv. Exp. Med. Biol."},{"key":"6006_CR38","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1002\/med.21572","volume":"39","author":"K Dabrowska","year":"2019","unstructured":"Dabrowska, K. Phage therapy: what factors shape phage pharmacokinetics and bioavailability? Systematic and critical review. Med. Res. Rev. 39, 2000\u20132025 (2019).","journal-title":"Med. Res. Rev."},{"key":"6006_CR39","first-page":"733","volume":"25","author":"LL Peng","year":"2009","unstructured":"Peng, L. L. et al. Therapeutic effect of bacteriophage D29 in the treatment for guinea pigs infected with sensitive strain of Mycobacterium tuberculosis. Chin. J. Zoonoses 25, 733\u2013736 (2009).","journal-title":"Chin. J. Zoonoses"},{"key":"6006_CR40","first-page":"209","volume":"4","author":"L Sula","year":"1981","unstructured":"Sula, L., Sulova, J. & Stolcpartova, M. Therapy of experimental tuberculosis in guinea pigs with mycobacterial phages DS-6A, GR-21 T, My-327. Czech Med. 4, 209\u2013214 (1981).","journal-title":"Czech Med."},{"key":"6006_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1006\/jmbi.1997.1610","volume":"279","author":"ME Ford","year":"1998","unstructured":"Ford, M. E., Sarkis, G. J., Belanger, A. E., Hendrix, R. W. & Hatfull, G. F. Genome structure of mycobacteriophage D29: implications for phage evolution. J. Mol. Biol. 279, 143\u2013164 (1998).","journal-title":"J. Mol. Biol."},{"key":"6006_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev-virology-091919-074222","volume":"8","author":"DP Pires","year":"2021","unstructured":"Pires, D. P., Melo, L. D. R. & Azeredo, J. Understanding the complex phage-host interactions in biofilm communities. Annu. Rev. Virol. 8, 73\u201394 (2021).","journal-title":"Annu. Rev. Virol."},{"key":"6006_CR43","doi-asserted-by":"publisher","first-page":"110825","DOI":"10.1016\/j.celrep.2022.110825","volume":"39","author":"R Delattre","year":"2022","unstructured":"Delattre, R. et al. Combination of in vivo phage therapy data with in silico model highlights key parameters for pneumonia treatment efficacy. Cell Rep. 39, 110825 (2022).","journal-title":"Cell Rep."},{"key":"6006_CR44","doi-asserted-by":"publisher","first-page":"L731","DOI":"10.1152\/ajplung.00309.2014","volume":"308","author":"K Brune","year":"2015","unstructured":"Brune, K., Frank, J., Schwingshackl, A., Finigan, J. & Sidhaye, V. K. Pulmonary epithelial barrier function: some new players and mechanisms. Am. J. Physiol. Lung Cell. Mol. Physiol. 308, L731\u2013745 (2015).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"6006_CR45","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.1128\/IAI.70.11.6251-6262.2002","volume":"70","author":"KE Cerveny","year":"2002","unstructured":"Cerveny, K. E., DePaola, A., Duckworth, D. H. & Gulig, P. A. Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect. Immun. 70, 6251\u20136262 (2002).","journal-title":"Infect. Immun."},{"key":"6006_CR46","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1099\/jmm.0.2008\/002873-0","volume":"57","author":"S Chhibber","year":"2008","unstructured":"Chhibber, S., Kaur, S. & Kumari, S. Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J. Med. Microbiol. 57, 1508\u20131513 (2008).","journal-title":"J. Med. Microbiol."},{"key":"6006_CR47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/cid\/ciac453","volume":"76","author":"RM Dedrick","year":"2023","unstructured":"Dedrick, R. M. et al. Phage therapy of mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease. Clin. Infect. Dis. 76, 103\u2013112 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"6006_CR48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1128\/IAI.00709-10","volume":"79","author":"Y Feng","year":"2011","unstructured":"Feng, Y. et al. Exposure to cigarette smoke inhibits the pulmonary T-cell response to influenza virus and Mycobacterium tuberculosis. Infect. Immun. 79, 229\u2013237 (2011).","journal-title":"Infect. Immun."},{"key":"6006_CR49","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1165\/rcmb.2013-0300OC","volume":"50","author":"TA Tucker","year":"2014","unstructured":"Tucker, T. A. et al. Plasminogen activator inhibitor-1 deficiency augments visceral mesothelial organization, intrapleural coagulation, and lung restriction in mice with carbon black\/bleomycin-induced pleural injury. Am. J. Respir. Cell Mol. Biol. 50, 316\u2013327 (2014).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"6006_CR50","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s13337-021-00673-8","volume":"32","author":"A Archana","year":"2021","unstructured":"Archana, A., Patel, P. S., Kumar, R. & Nath, G. Neutralizing antibody response against subcutaneously injected bacteriophages in rabbit model. Virusdisease 32, 38\u201345 (2021).","journal-title":"Virusdisease"},{"key":"6006_CR51","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/vim.2013.0128","volume":"27","author":"M \u0141usiak-Szelachowska","year":"2014","unstructured":"\u0141usiak-Szelachowska, M. et al. Phage neutralization by sera of patients receiving phage therapy. Viral Immunol. 27, 295\u2013304 (2014).","journal-title":"Viral Immunol."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06006-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06006-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06006-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T03:09:59Z","timestamp":1709953799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-024-06006-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,9]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["6006"],"URL":"https:\/\/doi.org\/10.1038\/s42003-024-06006-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.01.23.525188","asserted-by":"object"}]},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,9]]},"assertion":[{"value":"4 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"294"}}